Skip to content

Author

M. I. Wilde

We have 3 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Impact of higher comorbidity burden on guideline-directed medical therapy in patients with heart failure with reduced ejection fraction

Patients with a higher comorbidity burden less often used quadruple therapy and had a worse prognosis, as well as its association with clinical outcomes, according to a prespecified subanalysis of the TITRATE-HF registry.

J. J. N. Krabbe, M. I. Wilde, A. Mosterd et al. · 0 citations
Open access Oct 2026

Impact of age on implementation and tolerability of guideline-directed medical therapy in heart failure with reduced ejection fraction

The need for improved implementation strategies to optimize guideline-directed therapy and dosing levels in the ageing HFrEF population is highlighted, with use of GDMT associated with better clinical outcomes, also among older patients.

J. J. N. Krabbe, M. I. Wilde, W. L. Verloop et al. · 0 citations
Open access Jul 2026

Differences between men and women in guideline-directed medical therapy implementation, tolerability, and outcomes in heart failure with reduced ejection fraction.

The findings underscore the need for implementation and dosing strategies that account for differences between men and women regarding GDMT implementation, side effects, change in left ventricular ejection fraction (LVEF), and clinical outcomes.

M. I. Wilde, J. J. N. Krabbe, L. J. Bouhuijzen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.